State Street Corp boosted its stake in Prothena Corporation PLC (NASDAQ:PRTA) by 10.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,181,365 shares of the biotechnology company’s stock after purchasing an additional 113,193 shares during the period. State Street Corp owned about 3.09% of Prothena Corporation PLC worth $63,932,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the stock. Palo Alto Investors LLC lifted its stake in Prothena Corporation PLC by 1.7% in the 2nd quarter. Palo Alto Investors LLC now owns 1,073,955 shares of the biotechnology company’s stock valued at $58,122,000 after purchasing an additional 18,100 shares during the last quarter. Cornerstone Capital Management Holdings LLC. lifted its stake in Prothena Corporation PLC by 2.3% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 18,018 shares of the biotechnology company’s stock valued at $974,000 after purchasing an additional 402 shares during the last quarter. Sectoral Asset Management Inc lifted its stake in Prothena Corporation PLC by 7.1% in the 2nd quarter. Sectoral Asset Management Inc now owns 151,046 shares of the biotechnology company’s stock valued at $8,175,000 after purchasing an additional 10,000 shares during the last quarter. Voya Investment Management LLC lifted its stake in Prothena Corporation PLC by 4.0% in the 2nd quarter. Voya Investment Management LLC now owns 241,547 shares of the biotechnology company’s stock valued at $13,073,000 after purchasing an additional 9,374 shares during the last quarter. Finally, Hood River Capital Management LLC lifted its stake in Prothena Corporation PLC by 2.7% in the 2nd quarter. Hood River Capital Management LLC now owns 194,074 shares of the biotechnology company’s stock valued at $10,503,000 after purchasing an additional 5,138 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/10/31/state-street-corp-raises-position-in-prothena-corporation-plc-prta.html.

In other news, Director Christopher S. Henney sold 900 shares of the business’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $70.00, for a total value of $63,000.00. Following the completion of the sale, the director now directly owns 900 shares in the company, valued at approximately $63,000. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Tara Nickerson sold 17,500 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $63.60, for a total transaction of $1,113,000.00. Following the completion of the sale, the insider now owns 19,500 shares of the company’s stock, valued at $1,240,200. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,424 shares of company stock valued at $1,922,787. Company insiders own 3.10% of the company’s stock.

Several equities analysts recently commented on the stock. Royal Bank Of Canada reissued a “buy” rating on shares of Prothena Corporation PLC in a research note on Friday, September 29th. BTIG Research dropped their price objective on shares of Prothena Corporation PLC from $80.00 to $77.00 and set a “buy” rating for the company in a research note on Friday, September 29th. Cantor Fitzgerald reissued a “buy” rating and issued a $79.00 price objective on shares of Prothena Corporation PLC in a research note on Thursday, September 28th. Jefferies Group LLC reissued a “buy” rating and issued a $100.00 price objective on shares of Prothena Corporation PLC in a research note on Monday, October 2nd. Finally, SunTrust Banks, Inc. reissued a “buy” rating and issued a $75.00 price objective on shares of Prothena Corporation PLC in a research note on Monday, October 2nd. One analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company. Prothena Corporation PLC currently has a consensus rating of “Buy” and an average price target of $78.58.

Prothena Corporation PLC (PRTA) opened at 57.89 on Tuesday. Prothena Corporation PLC has a 12 month low of $40.58 and a 12 month high of $70.00. The firm has a 50-day moving average of $61.89 and a 200 day moving average of $58.09. The firm’s market capitalization is $2.22 billion.

Prothena Corporation PLC (NASDAQ:PRTA) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.43. The firm had revenue of $26.81 million during the quarter, compared to analyst estimates of $16.08 million. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. The business’s quarterly revenue was up 7951.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.18) EPS. Equities research analysts forecast that Prothena Corporation PLC will post ($4.41) earnings per share for the current year.

Prothena Corporation PLC Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.